HERON THERAPEUTICS, INC. /DE/ SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction of $127.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesDeductions · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2026-06-30 was $65.23M, a 2.31% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2026-03-31 was $62.00M, a 2.14% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2025-12-31 was $65.56M.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for the quarter ending 2025-09-30 was $63.45M, a 9.17% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for fiscal 2025 was $259.13M.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for fiscal 2024 was -$235.64M.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for fiscal 2023 was -$192.80M.
- HERON THERAPEUTICS, INC. /DE/ sec schedule, 12-09, valuation allowances and reserves, deduction for fiscal 2022 was -$170.33M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $127.22M 10-Q · filed 2026-08-10 | $192.78M derived: sum of 3 quarters · filed 2026-08-10 | $256.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $62.00M 10-Q · filed 2026-05-11 | $127.56M derived: sum of 2 quarters · filed 2026-05-11 | $191.00M derived: sum of 3 quarters · filed 2026-05-11 | $257.77M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | $65.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $129.01M derived: sum of 2 quarters · filed 2026-02-26 | $195.77M derived: sum of 3 quarters · filed 2026-02-26 | $259.13M 10-K · filed 2026-02-26 |
| 2025-09-30 | $63.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $130.21M derived: sum of 2 quarters · filed 2025-11-04 | $193.57M 10-Q · filed 2025-11-04 | -$214.57M derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | $66.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $130.12M 10-Q · filed 2025-08-08 | -$278.01M derived: sum of 3 quarters · filed 2025-08-08 | -$219.90M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $63.35M 10-Q · filed 2025-05-06 | -$344.78M derived: sum of 2 quarters · filed 2025-05-06 | -$286.66M derived: sum of 3 quarters · filed 2025-05-06 | -$224.43M derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | -$408.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$350.02M derived: sum of 2 quarters · filed 2025-02-27 | -$287.79M derived: sum of 3 quarters · filed 2025-02-27 | -$235.64M 10-K · filed 2025-02-27 |
| 2024-09-30 | $58.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $120.35M derived: sum of 2 quarters · filed 2024-11-12 | $172.49M 10-Q · filed 2024-11-12 | -$165.76M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $62.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $114.38M 10-Q · filed 2024-08-06 | -$223.87M derived: sum of 3 quarters · filed 2024-08-06 | -$160.93M derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | $52.15M 10-Q · filed 2024-05-07 | -$286.10M derived: sum of 2 quarters · filed 2024-05-07 | -$223.16M derived: sum of 3 quarters · filed 2024-05-07 | -$185.68M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$338.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$275.31M derived: sum of 2 quarters · filed 2024-03-12 | -$237.82M derived: sum of 3 quarters · filed 2024-03-12 | -$192.80M 10-K · filed 2024-03-12 |
| 2023-09-30 | $62.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $100.43M derived: sum of 2 quarters · filed 2023-11-14 | $145.45M 10-Q · filed 2023-11-14 | -$151.45M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $37.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $82.51M 10-Q · filed 2023-08-14 | -$214.39M derived: sum of 3 quarters · filed 2023-08-14 | -$170.38M derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | $45.02M 10-Q · filed 2023-05-11 | -$251.88M derived: sum of 2 quarters · filed 2023-05-11 | -$207.86M derived: sum of 3 quarters · filed 2023-05-11 | -$163.16M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -$296.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$252.89M derived: sum of 2 quarters · filed 2023-03-29 | -$208.19M derived: sum of 3 quarters · filed 2023-03-29 | -$170.33M 10-K · filed 2023-03-29 |
| 2022-09-30 | $44.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $88.71M derived: sum of 2 quarters · filed 2022-11-08 | $126.57M 10-Q · filed 2022-11-08 | -$156.86M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | $44.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $82.56M 10-Q · filed 2022-08-09 | -$200.87M derived: sum of 3 quarters · filed 2022-08-09 | -$160.63M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | $37.86M 10-Q · filed 2022-05-09 | -$245.57M derived: sum of 2 quarters · filed 2022-05-09 | -$205.33M derived: sum of 3 quarters · filed 2022-05-09 | -$164.35M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | -$283.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$243.19M derived: sum of 2 quarters · filed 2022-02-28 | -$202.22M derived: sum of 3 quarters · filed 2022-02-28 | -$161.68M 10-K · filed 2022-02-28 |
| 2021-09-30 | $40.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $81.22M derived: sum of 2 quarters · filed 2021-11-03 | $121.75M 10-Q · filed 2021-11-03 | -$97.22M derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | $40.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $81.51M 10-Q · filed 2021-08-09 | -$137.46M derived: sum of 3 quarters · filed 2021-08-09 | -$108.45M derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | $40.53M 10-Q · filed 2021-05-10 | -$178.43M derived: sum of 2 quarters · filed 2021-05-10 | -$149.43M derived: sum of 3 quarters · filed 2021-05-10 | -$116.11M derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-12-31 | -$218.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$189.96M derived: sum of 2 quarters · filed 2021-02-24 | -$156.64M derived: sum of 3 quarters · filed 2021-02-24 | -$122.43M 10-K · filed 2021-02-24 |
| 2020-09-30 | $29.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $62.32M derived: sum of 2 quarters · filed 2020-11-05 | $96.53M 10-Q · filed 2020-11-05 | -$170.77M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $33.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $67.53M 10-Q · filed 2020-08-05 | -$199.78M derived: sum of 3 quarters · filed 2020-08-05 | -$153.59M derived: sum of 4 quarters · filed 2020-08-05 |
| 2020-03-31 | $34.21M 10-Q · filed 2020-05-06 | -$233.09M derived: sum of 2 quarters · filed 2020-05-06 | -$186.91M derived: sum of 3 quarters · filed 2020-05-06 | -$151.79M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | -$267.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$221.12M derived: sum of 2 quarters · filed 2020-03-02 | -$186.00M derived: sum of 3 quarters · filed 2020-03-02 | -$159.76M 10-K · filed 2020-03-02 |
| 2019-09-30 | $46.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $81.30M derived: sum of 2 quarters · filed 2019-11-12 | $107.54M 10-Q · filed 2019-11-12 | $129.10M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | $35.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $61.35M 10-Q · filed 2019-08-05 | $82.91M derived: sum of 3 quarters · filed 2019-08-05 | $91.87M derived: sum of 4 quarters · filed 2019-08-05 |
| 2019-03-31 | $26.24M 10-Q · filed 2019-05-09 | $47.79M derived: sum of 2 quarters · filed 2019-05-09 | $56.75M derived: sum of 3 quarters · filed 2019-05-09 | $67.11M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-12-31 | $21.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $30.52M derived: sum of 2 quarters · filed 2019-02-22 | $40.88M derived: sum of 3 quarters · filed 2019-02-22 | $50.34M 10-K · filed 2019-02-22 |
| 2018-09-30 | $8.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $19.32M derived: sum of 2 quarters · filed 2018-11-07 | $28.78M 10-Q · filed 2018-11-07 | $33.23M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | $10.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $19.82M 10-Q · filed 2018-08-08 | $24.28M derived: sum of 3 quarters · filed 2018-08-08 | $28.03M derived: sum of 4 quarters · filed 2018-08-08 |
| 2018-03-31 | $9.46M 10-Q · filed 2018-05-10 | $13.92M derived: sum of 2 quarters · filed 2018-05-10 | $17.67M derived: sum of 3 quarters · filed 2018-05-10 | $19.38M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $8.21M derived: sum of 2 quarters · filed 2018-02-27 | $9.91M derived: sum of 3 quarters · filed 2018-02-27 | $10.28M 10-K · filed 2018-02-27 |
| 2017-09-30 | $3.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $5.46M derived: sum of 2 quarters · filed 2017-11-06 | $5.82M 10-Q · filed 2017-11-06 | |
| 2017-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.06M 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $362.00K 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |